Quidelortho CORP 8-K filings

QuidelOrtho Corporation announced the results of its 2026 Annual Meeting of Stockholders, including the election of ten directors and the ratification of its independent auditor.

QuidelOrtho announced first quarter 2026 financial results, reporting $620 million in total revenue, and updated its full-year 2026 financial guidance.

QuidelOrtho announced preliminary Q1 2026 revenue of $615-$620 million, citing a weak respiratory season and geopolitical disruptions.

QuidelOrtho Corporation announced the retirement of its Chief Legal Officer, Michelle A. Hodges, and the appointment of Nathaniel Sisitsky as her successor, effective March 23, 2026.

QuidelOrtho Corporation's Chief Financial Officer, Joseph M. Busky, will retire effective June 30, 2026, for personal reasons.

QuidelOrtho announced its fourth quarter and full-year 2025 financial results, highlighting growth in core diagnostics and significant margin expansion, alongside a positive outlook for 2026.

Matthew W. Strobeck will not stand for re-election to QuidelOrtho's board, leading to a reduction in board size from eleven to ten directors.

QuidelOrtho reports strong third-quarter 2025 results with improved adjusted EBITDA margins, significant cost savings, and solid underlying revenue growth driven by non-respiratory and international segments.

QuidelOrtho Corporation announced third quarter 2025 financial results, reporting total revenue of $700 million and a significant non-cash goodwill impairment charge of $701 million.

QuidelOrtho Corporation successfully refinances its debt structure, securing $3.4 billion in new credit facilities to extend maturities and enhance financial flexibility for future growth.

QuidelOrtho reported a 330 basis point improvement in adjusted EBITDA margin and achieved $100 million in annualized cost savings in Q2 2025, despite a 3.6% total revenue decrease.

QuidelOrtho Corporation's stockholders have approved the Second Amended and Restated 2018 Equity Incentive Plan, increasing authorized shares by 6.2 million and extending its term, alongside the re-election of all eleven director nominees and executive compensation.

QuidelOrtho announced its first quarter 2025 financial results, reporting a 5% revenue increase and maintaining its full-year financial guidance.

QuidelOrtho Corporation has appointed KPMG as its new independent registered public accounting firm, replacing Ernst & Young, effective February 28, 2025.

QuidelOrtho's Q4 2024 revenue was $708 million, and the company is focusing on cost-saving initiatives to improve adjusted EBITDA margins in 2025 and beyond.

QuidelOrtho reports preliminary unaudited fourth-quarter revenue for 2024, aligning with previous financial guidance.

QuidelOrtho Corporation has appointed John R. Chiminski and R. Scott Huennekens as independent directors to its board, effective December 6, 2024.

QuidelOrtho Corporation announced the pricing of a secondary offering by a major shareholder and the resignation of two board members following the sale.

QuidelOrtho Corporation has increased the base salary of its Chief Financial Officer, Joseph M. Busky, to $680,000, effective November 18, 2024, as part of a leadership reorganization.

QuidelOrtho Corporation has amended its previous 8-K filing to disclose the approved compensation terms for its newly appointed Chief Operations Officer, Philip McLellan.

QuidelOrtho has announced a leadership reorganization, including the termination of two executive vice presidents and the appointment of a new Chief Operations Officer, effective November 15, 2024.

QuidelOrtho announced its third quarter 2024 financial results, reinstating its full-year 2024 financial guidance and highlighting cost-saving initiatives.

QuidelOrtho's second quarter results show a revenue decrease due to lower COVID-19 sales, but recurring revenue grew, and the company is implementing cost-saving measures.

QuidelOrtho Corporation held its 2024 Annual Meeting of Stockholders on May 14, 2024, where all proposals were approved, including the election of ten directors, executive compensation, and the ratification of the company's accounting firm.

QuidelOrtho's first quarter results show a 5% revenue increase, but a significant GAAP loss due to a goodwill impairment, leading to the suspension of 2024 financial guidance.

QuidelOrtho Corporation has appointed Brian J. Blaser as its new President and CEO, effective May 6, 2024, and expanded its board to include him as a director.

QuidelOrtho Corporation has modified its credit agreement, adjusting the maximum leverage ratio requirements over the next few years.

QuidelOrtho has amended its previous 8-K filing to disclose the approved retention compensation for its interim CEO, interim president, and CFO, including increased bonus targets and significant cash and equity awards.

QuidelOrtho's CEO, Douglas C. Bryant, has been terminated, and an Office of the CEO has been formed with Michael S. Iskra as Interim CEO and Robert J. Bujarski as Interim President.

QuidelOrtho has updated its 2024 financial guidance, widening the range for adjusted diluted EPS while maintaining the midpoint.